Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | BTK | Q06187 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158576 | 0.98 | IKBKB (0.75) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL4711452 | 0.90 | PTPN1 (0.64) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL875389 | 0.87 | IKBKB (0.60) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL1847243 | 0.87 | IKBKB (1.00) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL29906389 | 0.87 | IKBKB (0.60) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL4086036 | 0.87 | IKBKB (0.60) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL4119811 | 0.86 | MAPT (1.00) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL4082306 | 0.85 | TUBB4A (0.66) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL3081896 | 0.84 | MAPT (0.63) | IKBKBCYP1A2CYP3A4CYP2C9BTK | |
| SCHEMBL15881509 | 0.84 | MAPT (0.59) | IKBKBCYP1A2CYP3A4CYP2C9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813509-B1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | ASTRAZENECA AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2721036-B1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS | TAKEDA GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-9018175-B2 | 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives | TAKEDA GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2813509-A1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | Takeda GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014111666-A1 | THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AND THE PREPARATION AND PHARMACEUTICAL USES THEREOF | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-07-24 | — | — | WO | disclosed |
| EP-2513119-B1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-C]ISOQUINOLINE DERIVATIVES | TAKEDA GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20140113877-A1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C] ISOQUINOLINE COMPOUNDS | TAKEDA GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2721036-A1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS | Takeda GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070078125-A1 | Arylamine mch r1 antagonists | GLAXO GROUP LIMITED | 2007-04-05 | — | — | US | disclosed |
| US-20070078125-A1 | Arylamine mch r1 antagonists | GLAXO GROUP LIMITED | 2007-04-05 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | disclosed |
| US-20040116509-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2004-06-17 | — | — | US | disclosed |
| EP-1401825-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | Shire Biochem Inc. (CA) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002100851-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113877-A1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C] ISOQUINOLINE COMPOUNDS | PDE4A, PDE4B, PDE3B | IKBKB 2552/4885CYP1A2 93/4885CYP3A4 22/4885 |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | IKBKB 1105/4885CYP1A2 909/4885CYP3A4 622/4885 |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | IKBKB 1105/4885CYP1A2 909/4885CYP3A4 622/4885 |
| US-20070078125-A1 | Arylamine mch r1 antagonists | MCHR1, MCHR2, MC1R | IKBKB 3708/4885CYP1A2 440/4885CYP3A4 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.